An application of alginate sulfate in the preparation of drugs and health care products for preventing and treating diseases caused by human papillomavirus. Alginate sulfate has a strong dose-dependent inhibitory effect on HPV infection through experiments, and alginate sulfate inhibited the expression of E6 and E7 genes and proteins in HPV-transformed Hela and Caski cells in a dose-dependent manner. The alginate sulfate can be developed into a drug or a health care product against human papillomavirus by systematic scientific experiments, which will have a good market application prospect.

A self-foaming composition is described that includes clobetasol propionate, for a no-rinse topical application and for application to the skin. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and clobetasol propionate being present in at least one of the intermediate compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition.

An antiviral treatment of infections from Coronavirus, in particular COVID-19, is by administration of a modified nucleoside, derived from adenosine, individually or in combination with other therapeutically active substances. In particular, 3′-deoxyadenosine, or cordycepin, is administered for the treatment of a viral syndrome from Coronavirus, in particular COVID-19, in which 3′-deoxyadenosine is administered individually or in combination with at least one inhibitor or antagonist of the adenosine receptors A1 and A3 and possibly agonist of the adenosine receptors A.sub.2a and/or A.sub.2b. The administration of 3′-deoxyadenosine is subsequent or simultaneous to the administration of the inhibitor, preferably inosine, a molecule which expresses both these functions.

This invention relates generally to compositions useful for the maintenance of calcium homeostasis. In particular, this invention is directed to apoaequorin-containing effervescent compositions useful in preventing and/or alleviating diseases or symptoms associated with calcium imbalance. Certain embodiments of the invention further contain active ingredients including at least one stimulant (e.g., caffeine) and/or vitamin D.

One solid preparation of the present invention mainly includes silicon fine particles, and has a capability of generating hydrogen. In addition, one specific example of the solid preparation mainly includes silicon fine particles having a crystallite diameter principally of 1 nm or more and 100 nm or less, and exhibits a capability of generating hydrogen in an amount of 3 ml/g or more when brought into contact with a water-containing liquid having a pH value of 7 or more. In this solid preparation, hydrogen is generated when the silicon fine particles are brought into contact with a water-containing liquid having a pH value of 7 or more. Therefore, taking advantage of the characteristics of the solid preparation, generation of hydrogen is promoted in, for example, a gastrointestinal tract where the pH value is 7 or more due to secretion of pancreatic fluid after passage through the stomach after oral ingestion.

Effervescent gel EG agent is a new oral formulation platform. It includes a fast-expanding gel agent, a foam-forming agent, an active ingredient, and an auxiliary ingredient. Effervescent gel is mixed with appropriate amount of aqueous agent or aqueous solution, which can swell rapidly (generally less than 30 seconds) and form a uniform multi-bubble hydrogel, which has the characteristics of fast gel formation, convenient preparation, uniform gel, smooth taste and adjustable viscosity, especially for children, the elderly and patients with swallowing reflex dysfunction. Oral effervescent gels are convenient, safe and have excellent taste, and significantly increase the compliance of pediatric patients, and can be used in the fields of pharmaceuticals, food and health products.

One solid preparation of the present invention mainly includes silicon fine particles, and has a capability of generating hydrogen. In addition, one specific example of the solid preparation mainly includes silicon fine particles having a crystallite diameter principally of 1 nm or more and 100 nm or less, and exhibits a capability of generating hydrogen in an amount of 3 ml/g or more when brought into contact with a water-containing liquid having a pH value of 7 or more. In this solid preparation, hydrogen is generated when the silicon fine particles are brought into contact with a water-containing liquid having a pH value of 7 or more. Therefore, taking advantage of the characteristics of the solid preparation, generation of hydrogen is promoted in, for example, a gastrointestinal tract where the pH value is 7 or more due to secretion of pancreatic fluid after passage through the stomach after oral ingestion.

An effervescent tablet that exhibits rapid disintegration is disclosed. The effervescent tablet includes an effervescent agent that includes an acid and a base, a crystalline sugar binder selected from the group consisting of crystalline dextrose, crystalline sucrose, crystalline fructose, and combinations thereof, the crystalline sugar binder being essentially free of excipients, a sweetener that includes at least one of Stevia and Monk fruit, a flavor agent that includes a gum Arabic carrier, and optionally a lubricant derived from rice hulls (e.g., a multi-component integral lubricant).

Separable microneedle arrays and microneedle patches are provided that may achieve sustained release of drug. The microneedle arrays may include one or more features that facilitate separation of the microneedles, such as a bubble structure. The microneedle arrays may include an effervescent material.

The invention provides a method for the preparation of effervescent granules wherein the reactive, effervescent components (one acidic and one alkaline CO.sub.2-generating component) are brought to reaction with one another under stirring in a vacuum (100-900 mbar) in an evacuable mixing chamber, with said mixing chamber being evacuated to a first vacuum value p.sub.1, and then ‘re-evacuated’ to said first vacuum value p.sub.1 again, optionally repeatedly, once the pressure has increased to a second vacuum value p.sub.2 due to the progressing CO.sub.2 formation of the effervescent reaction. The method is carried out in such a way that during at least the effervescent reaction step(s) the stirring speed in the mixing chamber exhibits a Froude number (Fr) of 0.5 or higher, preferably 0.8 or higher, more preferably 0.9 or higher; such as, in the range of 0.50 to 8.00, or 0.80 to 8.00, or 0.90 to 8.00.